Skip to content

Study · Animal study (in vivo) · rat · 1999

4 results

Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats.

Malmlöf K, Johansen PB, Haahr PM, Wilken M, Oxlund H

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society1 Dec 1999Cited by 5 (Europe PMC)

PMID10629165 (opens in a new tab)DOI10.1054/ghir.1999.0128 (opens in a new tab)PepBankPUB-10629165
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats given methylprednisolone for 8 days, the acute plasma GH response to ipamorelin did not change compared with saline-treated rats.

    In plain wordsIn rats given a glucocorticoid, the growth hormone response to ipamorelin was not reduced compared with saline-treated rats.

    Peptide
    Ipamorelin
    Outcome
    No significant changeAcute plasma GH response to ipamorelin in methylprednisolone-treated rats
    Study

    ratn: not reported in source

    Rats given methylprednisolone
    Comparator
    Saline-treated rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenous · 8 days of MP treatment before acute testAs given in this study (rat).

    Source sentences

    Summary
    Treatment with MP significantly (P< 0.001) decreased body weight gain, but the acute response to either IPA or growth hormone releasing hormone (GHRH) in terms of plasma GH was not changed.
    1 context sentence
    Summary · context
    In a first experiment, rats received either saline or MP (5.0 mg/kg) for 8 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats given methylprednisolone, high-dose ipamorelin significantly reduced body weight loss compared with methylprednisolone alone.

    In plain wordsIn rats given a glucocorticoid, high-dose ipamorelin reduced weight loss compared with the glucocorticoid alone.

    Peptide
    Ipamorelin
    Outcome
    DecreaseBody weight loss with MP plus high-dose ipamorelin
    Study

    ratn: not reported in source

    Rats given methylprednisolone
    Comparator
    Methylprednisolone alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.6 mg/kg/day · intravenous · 10 daysAs given in this study (rat).

    Measurements

    Body weight loss
    2.3 g
    MP plus high-dose IPA

    Source sentences

    Summary
    When IPA was given together with MP, losses in body weight were significantly (P< 0.05) reduced to 2.3 +/- 2.0
    2 context sentences
    Summary · context
    high and low dose of IPA, respectively.
    Summary · context
    On the next day, rats were randomly allocated to receive saline alone, MP alone (5.0 mg/kg) or MP plus IPA in doses of 0.4 or 1.6 mg/kg/day for 10 days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats given methylprednisolone, low-dose ipamorelin significantly reduced body weight loss compared with methylprednisolone alone.

    In plain wordsIn rats given a glucocorticoid, low-dose ipamorelin reduced weight loss compared with the glucocorticoid alone.

    Peptide
    Ipamorelin
    Outcome
    DecreaseBody weight loss with MP plus low-dose ipamorelin
    Study

    ratn: not reported in source

    Rats given methylprednisolone
    Comparator
    Methylprednisolone alone
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.4 mg/kg/day · intravenous · 10 daysAs given in this study (rat).

    Measurements

    Body weight loss
    1.6 g
    MP plus low-dose IPA

    Source sentences

    Summary
    When IPA was given together with MP, losses in body weight were significantly (P< 0.05) reduced to 2.3 +/- 2.0 and 1.6 +/- 2.0 g
    1 context sentence
    Summary · context
    On the next day, rats were randomly allocated to receive saline alone, MP alone (5.0 mg/kg) or MP plus IPA in doses of 0.4 or 1.6 mg/kg/day for 10 days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats given methylprednisolone, repeated ipamorelin was accompanied by increased IGF-I levels.

    In plain wordsIn rats given a glucocorticoid, repeated ipamorelin was accompanied by higher IGF-I levels.

    Peptide
    Ipamorelin
    Outcome
    IncreaseIGF-I levels
    Study

    ratn: not reported in source

    Rats given methylprednisolone
    Comparator
    Methylprednisolone alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.4 and 1.6 mg/kg/day · intravenous · 10 daysAs given in this study (rat).

    Source sentences

    Summary
    In parallel with this IGF-I levels increased.
    1 context sentence
    Summary · context
    On the next day, rats were randomly allocated to receive saline alone, MP alone (5.0 mg/kg) or MP plus IPA in doses of 0.4 or 1.6 mg/kg/day for 10 days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.